<?xml version="1.0" encoding="UTF-8"?>
<abstract id="abs0010">
 <p>Type 1 interferons have a broad antiviral activity 
  <italic>in vitro</italic> and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.
 </p>
</abstract>
